Bioscience

Transgenomic and Power3 Medical report identification of abnormal serum

September 2, 2009

By Flinn Foundation

[Source: Reuters] – Transgenomic, Inc. and Power3 Medical Products, Inc. today announced the advance on-line publication of a clinical research paper entitled “Abnormal Serum Concentrations of Proteins in Parkinson’s Disease” in the scientific journal Biochemical and Biophysical Research Communications. The study demonstrates the usefulness of a protein biomarker panel to distinguish Parkinson’s disease (PD) patients from age-matched normal controls independent of the severity of symptoms, using clinical blood serum samples.

The analytic technology forms the basis for the NuroPro(R)PD test for PD being commercialized by Transgenomic as per a licensing/collaboration agreement with Power3 Medical signed in early 2009.  The publication of the peer-reviewed article is a significant validation milestone in the ongoing clinical development of the NuroProPD diagnostic assay.

For more information: Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinson’s Disease